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Reporting and analysis of repeated measurements in preclinical animals
experiments
Abstract
A common feature of preclinical animal experiments is repeated measurement of the outcome, e.g., body
weight measured in mice pups weekly for 20 weeks. Separate time point analysis or repeated measures analysis
approaches can be used to analyze such data. Each approach requires assumptions about the underlying data
and violations of these assumptions have implications for estimation of precision, and type I and type II error
rates. Given the ethical responsibilities to maximize valid results obtained from animals used in research, our
objective was to evaluate approaches to reporting repeated measures design used by investigators and to assess
how assumptions about variation in the outcome over time impact type I and II error rates and precision of
estimates. We assessed the reporting of repeated measures designs of 58 studies in preclinical animal
experiments. We used simulation modelling to evaluate three approaches to statistical analysis of repeated
measurement data. In particular, we assessed the impact of (a) repeated measure analysis assuming that the
outcome had non-constant variation at all time points (heterogeneous variance) (b) repeated measure
analysis assuming constant variation in the outcome (homogeneous variance), (c) separate ANOVA at
individual time point in repeated measures designs. The evaluation of the three model fitting was based on
comparing the p-values distributions, the type I and type II error rates and by implication, the shrinkage or
inflation of standard error estimates from 1000 simulated dataset. Of 58 studies with repeated measures
design, three provided a rationale for repeated measurement and 23 studies reported using a repeated-
measures analysis approach. Of the 35 studies that did not use repeated-measures analysis, fourteen studies
used only two time points to calculate weight change which potentially means collected data was not fully
utilized. Other studies reported only select time points (n = 12) raising the issue of selective reporting.
Simulation studies showed that an incorrect assumption about the variance structure resulted in modified
error rates and precision estimates. The reporting of the validity of assumptions for repeated measurement
data is very poor. The homogeneous variation assumption, which is often invalid for body weight
measurements, should be confirmed prior to conducting the repeated-measures analysis using homogeneous
covariance structure and adjusting the analysis using corrections or model specifications if this is not met.
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Abstract
A common feature of preclinical animal experiments is repeated measurement of the out-
come, e.g., body weight measured in mice pups weekly for 20 weeks. Separate time point
analysis or repeated measures analysis approaches can be used to analyze such data.
Each approach requires assumptions about the underlying data and violations of these
assumptions have implications for estimation of precision, and type I and type II error
rates. Given the ethical responsibilities to maximize valid results obtained from animals
used in research, our objective was to evaluate approaches to reporting repeated mea-
sures design used by investigators and to assess how assumptions about variation in the
outcome over time impact type I and II error rates and precision of estimates. We
assessed the reporting of repeated measures designs of 58 studies in preclinical animal
experiments. We used simulation modelling to evaluate three approaches to statistical
analysis of repeated measurement data. In particular, we assessed the impact of (a)
repeated measure analysis assuming that the outcome had non-constant variation at all
time points (heterogeneous variance) (b) repeated measure analysis assuming constant
variation in the outcome (homogeneous variance), (c) separate ANOVA at individual time
point in repeated measures designs. The evaluation of the three model fitting was based
on comparing the p-values distributions, the type I and type II error rates and by implica-
tion, the shrinkage or inflation of standard error estimates from 1000 simulated dataset. Of
58 studies with repeated measures design, three provided a rationale for repeated mea-
surement and 23 studies reported using a repeated-measures analysis approach. Of the
35 studies that did not use repeated-measures analysis, fourteen studies used only two
time points to calculate weight change which potentially means collected data was not fully
utilized. Other studies reported only select time points (n = 12) raising the issue of selec-
tive reporting. Simulation studies showed that an incorrect assumption about the variance
structure resulted in modified error rates and precision estimates. The reporting of the
validity of assumptions for repeated measurement data is very poor. The homogeneous
variation assumption, which is often invalid for body weight measurements, should be
confirmed prior to conducting the repeated-measures analysis using homogeneous
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covariance structure and adjusting the analysis using corrections or model specifications if
this is not met.
Introduction
A repeated measures design element refers to the practice of measuring the outcome on each
study unit multiple times. Most frequently the multiple measurements occur over time,
although other factors can be studied such as repeated exposure of individuals to changing lev-
els of sound or light. Our interest in the approaches to the use of repeated measurements in
preclinical animal experiments relate to the impact of statistical analysis on the reproducibility
and reliability of results [1]. If the assumptions of statistical tests are violated, there is the
potential issue that the estimates of variation are incorrect and type I and II errors are not
appropriately controlled. There has been concern that increased type I error rates and reduced
variation estimates can contribute to the reproducibility crisis in biomedical research due to
the preference to publish significant results [2, 3]. However, equally important is the fact that
variance and type II error rate inflation can mean studies with important findings might
remain unpublished due to publication bias. The solution to these issues is appropriate analysis
based on the underlying data structure that minimizes both types of errors and provides accu-
rate estimates of precision.
Repeated measures is a very common study design element in preclinical animal research.
In a survey of 200 preclinical animal experiments, 58 manuscripts contained language that
described the repeated measurement of at least one outcome on study subjects [4]. Inclusion
of a repeated measurements design element can be desirable for a variety of reasons. Repeated
measurement of outcomes is often included if the impact of the factor, time, or changes in the
effect of treatment over time are of explicit interest to the investigator. Studying multiple out-
comes for each subject might also allow investigators to reduce subject-to-subject and within-
subject variation in the investigation of the relative effects of different treatments. Reduced
variability might increase the study’s power, and this is another rationale for implementing
repeated measurements [5].
Repeated measures analyses are often conducted with either repeated measures ANOVAs
or multilevel modelling. Repeated measures ANOVAs are common methods that rely on bal-
anced data and can be implemented with PROC GLM in SAS and ezANOVA in R. In con-
trast, multilevel models, which are usually implemented with Proc MIXED in SAS, lme4 or
nlme using R, or statsmodels for Python, allow for unbalanced data but require more elabo-
rate fitting algorithms and model specifications than repeated measures ANOVAs. In both
models, the specification of the variance covariance structure, which models the covariation
among measurements from the same subject, is the key step in the analysis of repeated mea-
sures. There are several variance covariance structures available for selection by analysts, and
many statistical software procedures implement the compound symmetry structure by
default. The compound symmetry variance covariance structure assumes that all the vari-
ances are equal and all the covariances are equal. These assumptions, however, might be
incorrect and a different structure might better describe the variance between subjects and
covariation within subjects. It is important to study the impact of making these incorrect
assumptions and choosing the wrong variance covariance structure in a repeated measures
analysis.
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Given the high frequency of repeated measurements design in preclinical animal experi-
ments and analysis with different approaches, our objectives in this study were to (i) summa-
rize how current researchers report studies with repeated measurements design; (ii) assess the
impact of choice of analysis approach of repeated measures using simulation modelling on the
p-value distributions, the type I, and type II error rates. For each of these aims, the knowledge
gained could be used to inform educational activities for researchers that promote approaches
to reporting and analysis that maximize the value obtained from animals used in preclinical
experiments.
Materials and method
Eligible studies and study selection
This project used a subset from 200 manuscripts used in another study that assessed the pres-
ence of seven design elements in preclinical animal experiments. The 200 studies are preclini-
cal experiments on brain trauma and toxicology, many with repeated measure design elements
that were identified for a different study. Eligible studies included described primary research
of a single comparative pre-clinical animal experiment [4]. Of the 200 studies, 100 studies were
randomly selected from eligible studies and characterized for the design features used by the
authors. This process included assessment of the design by two independent reviewers. The
studies used here are those that used a repeated measures design element. Fifty-eight of the
200 studies were classified as containing language that suggested repeated measurement of the
outcome i.e., a repeated measures design element. Two approaches to recognition of a repeated
measures design element were used. A repeated measures design element was one where the
investigators described a process of repeated measurements of outcomes on a study unit such
as measurement of animal body weight weekly for 10 weeks. Alternatively, if the investigators
described a statistical method that would be considered a repeated measures statistical analysis,
such as “a repeated measures ANOVA was conducted”, this was also used as evidence for a
repeated measures design. These two criteria were used to select all studies with repeated mea-
sures design elements (n = 58: designated for “repeated measures (RM) studies”). Within the
RM studies, a smaller subset of studies (n = 31) with body weight as the outcome (specified
with the prefix “BW-”) was also formed. Additionally, we differentiated repeated measurement
from pseudoreplication, another form of replication e.g., repeated measurement of the number
of cells on the same histopathology slide [6]. The distinction between the two forms of replica-
tion is that, unlike pseudoreplicates, repeated measurements are associated with another study
factor, such as time, that can be included in the data analysis.
Aim 1: Assessment of the rationale, approaches to analysis, and approach
to the reported results of analysis
We assessed the investigators’ rationale for inclusion of the repeated measures design ele-
ment by determining if the investigators provided either a description of treatment over time
in the objectives or a statement of the higher power with a repeated-measure analysis in com-
parison with single time point study (e.g., ANOVA at one time point) in the introduction
section.
For the assessment of approaches to analysis, for all studies, we extracted the number of
treatments and the number of time points assessed. We assessed if the 58 studies used
repeated-measures analysis (RMA) or not (NoRMA) and if the investigators reported assessing
the normality of residual errors and homogeneity of variance. Key phrases indicating the
repeated measures statistical analysis included “repeated-measures ANOVA”, “repeated
Reporting and analysis of repeated measurements in preclinical animals experiments
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measures analysis of variance”, and “MIXED model with subject as a random effect”, etc. Men-
tioning of assessment of normality or homogeneity of variance for at least one outcome was
designated as “yes”.
With respect to reporting the results, we determined if the investigators reported the follow-
ing when applicable: overall repeated measures model effect by specifying either main effect
including treatment effect, time effect, or treatment-by-time interaction, and test for treatment
at single time points. We also evaluated if the investigator presented the observed data from
each group at each time point in either a figure or table and whether the precision was
reported. As many investigations have multiple outcomes, a positive response (yes) was
recorded if the investigators provided the information of interest for at least one outcome. We
also examined the association between the meta-factors (year of publication, the first 24
months’ citations, journal impact factor in the published year, and journal impact factor in
2016) and the use of RMA analysis in the subset of 31 studies that reported the effect of treat-
ments on body weight. A detailed description of these variables is available in Supplementary
materials.
Aim 2: The impact of analysis approach on tests for treatment effects at
single time points
Aim 2 sought to evaluate the impact of different analysis approaches on repeated measures
data. This aim first required setting the parameters (the mean, the SD and the covariance
among subjects) for the observations in the simulation datasets. These parameters were then
combined with other simulation settings to create multiple datasets which varied in the sample
size, treatment effect on the outcome and the covariation among measurements from the same
subject. The impact of different approaches to statistical analysis were then evaluated. More
detail about these steps is provided below.
Parameter identification for simulation. With the purpose of empirical simulation, fig-
ure 2 of Cho et al. [6], which presented data for the effect of three dietary treatments on the
body weight of 11-12 mice per group weekly for 29 weeks, was selected as the basis for the sim-
ulation. The means and mean standard errors (SEMs) at five time points (week 1, 7, 14, 21 and
28) for each treatment combination were extracted using Plot Digitizer software version 2 [7].
The standard deviations (SDs) were obtained by multiplying the SEM by the square root of the
sample size of each group, which was set to 12.
Two simulations were conducted corresponding to a null model and an alternative model,
for assessment of type I error rates, type II error rates and SEM estimation. Under the null
model which equates to no treatment effect, the population mean parameter at each time point
was set as the average of the means of the three treatments at week 1, 7, 14, 21 and 28 from
Cho et al. [6]. The SDs used for each time point and treatment combination were those
extracted from the Cho et al. [6] as described above. The population parameters (means and
SEMs) of the alternative model at each time point were directly extracted from Cho et al. [6].
The only difference in the simulation parameters between the null and the alternative model
was the mean parameters, that is the null model has no group differences in contrast to the
alternative simulation model. All parameters used for simulation setting are summarized in
Table 1.
The simulation procedure. Two sets of simulations were conducted using the parameters
in Table 1. We varied the following conditions in the null and alternative model to create the
underlying data:
1. Two heterogeneous population variance covariance structures; heterogeneous compound
symmetry (heterogeneous_CS) as in Eq (1) or heterogeneous first order autoregressive
Reporting and analysis of repeated measurements in preclinical animals experiments
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(heterogeneous_AR) as in Eq (2). The rationale for creating a dataset with heterogeneous
variance is that the data from Cho et al appear to show that the variance of the outcome,
body weight, increases over time, which implies heterogeneous variance (Table 1 and S1
Fig). The covariance of heterogeneous compound symmetry assumes that the same cor-
relation ρ between observations at any two pairs of time points for the same subject. A
first-order autoregressive covariance assumes that correlations ρ decline exponentially
with distance, which means that as measurements get farther apart, they are less corre-
lated. Both structures of covariance are thought to frequently occur in repeated measures
data.
2. three sample sizes for each group (n = 3, 6, 12 per group);
3. four correlation coefficient ρ values (ρ = 0.1, 0.3, 0.6, 0.9), where correlation coefficients
were specified with regard to time points
Multivariate normal random variables with the specific mean and variance covariance
structures were simulated for each combination (2 × 3 × 4) of conditions 1,000 times.
Analysis on simulated data. Using the 2 × 3 × 4 simulated data output for either null or
alternative model, three statistical analysis approaches were conducted:
i. Repeated measures analysis (RMA) where the variance covariance structure in the model
correctly represents the underlying data.
For the data simulated with heterogeneous compound symmetry, the analysis would be
implemented using heterogeneous compound symmetry variance covariance structure
(heterogeneous_CS) as in Eq (1); For the data simulated by heterogeneous first order
Table 1. Parameters used for simulations approximated from Cho et al. (2013).
Treatment Time Mean in the null simulation Mean in the alternative simulation SEM SD
HFol-Hfol week 1 160 166.45 7.97 27.57
HFol-RV week 1 160 165.27 6.79 23.48
RV-RV week 1 160 149.92 6.00 20.76
HFol-Hfol week 7 480 478.77 8.26 28.59
HFol-RV week 7 480 492.34 12.98 44.92
RV-RV week 7 480 468.14 11.21 38.80
HFol-Hfol week 14 630 615.83 17.70 61.26
HFol-RV week 14 630 654.19 21.54 74.53
RV-RV week 14 630 619.96 15.34 53.09
HFol-Hfol week 21 724 697.41 19.48 67.38
HFol-RV week 21 724 752.89 26.85 92.91
RV-RV week 21 724 721.02 16.23 56.15
HFol-Hfol week 28 800 764.83 23.90 82.70
HFol-RV week 28 800 835.06 33.05 114.35
RV-RV week 28 800 790.21 15.64 54.11
HFol-HFol: 10-fold folate (HFol) diet for both mother and pup; HFol-RV: 10-fold folate (HFol) diet for mother, recommended vitamin is for pup; RV-RV:
recommended vitamin diet for both mother and pup. Data were approximated using Plot Digitizer. Mean in the alternative simulation: directly extracted mean value of
each treatment and time combination from Cho et al. [6]. Mean in the null simulation: average mean value of three treatments at week 1, 7, 14, 21, and 28 from mean
value in the alternative simulation. SEM was directly extracted from Cho et al. [6] and SD denotes for standard deviation calculated by SE �
ffiffiffiffiffi
12
p
(sample size per
group).
https://doi.org/10.1371/journal.pone.0220879.t001
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autoregressive, the correctly specified structure in the analysis would be the heteroge-
neous first order autoregressive variance covariance structure (heterogeneous_AR) as in
Eq (2);
heterogeneous compound symmetry ¼
s2
1
s1s2r s1s3r s1s4r s1s5r
s2
2
s2s3r s2s4r s2s5r
s2
3
s3s4r s3s5r
s2
4
s4s5r
s2
5
2
6
6
6
6
6
6
6
6
6
6
4
3
7
7
7
7
7
7
7
7
7
7
5
ð1Þ
heterogeneous first order autoregressive ¼
s2
1
s1s2r s1s3r
2 s1s4r
3 s1s5r
4
s2
2
s2s3r s2s4r
2 s2s5r
3
s2
3
s3s4r s3s5r
2
s2
4
s4s5r
s2
5
2
6
6
6
6
6
6
6
6
6
6
4
3
7
7
7
7
7
7
7
7
7
7
5
ð2Þ
The variance covariance matrices are symmetric with the value in diagonal representing
the variance at each time point and values off diagonal denoting covariance of pairwise
time points. Where s2
1
; s2
2
; s2
3
; s2
4
; and s2
5
on the diagonal represent variance at five time
point of the two structure above, and different subscript of σ2 designates unequal variance
ðs2
1
6¼ s2
2
6¼ s2
3
6¼ s2
4
6¼ s2
5
Þ. For off diagonal value: in the heterogeneous_CS structure as
in Eq (1), ρ (0� ρ� 1) is the constant correlation of pairwise time points, and σiσjρ(i 6¼ j)
is the covariance between timei and timej (e.g., σ1σ2ρ is the covariance between time1
and time2 of the same subject); in the heterogeneous_AR structure as in Eq (2), ρ(j−i) are
the correlations between timej and timei, and σiσjρ(j−i) represents covariance between
timei and timej (e.g., σ1σ3ρ(3−1) is the covariance between time1 and time3 of the same
subject).
ii. Repeated measures analysis (RMA) where the variance covariance structure in the model
does not correctly represent the underlying data due to equal variance assumption.
For the data simulated by heterogeneous compound symmetry variance covariance struc-
ture as in Eq (1), the incorrectly specified variance covariance structure was homoge-
neous compound symmetry (homogeneous_CS) as in Eq (3). This analysis approach is
commonly referred to as the compound symmetry (CS) or exchangeable structure and is
the default for most software procedures or packages. For data simulated by heteroge-
neous first order autoregressive variance covariance structure as in Eq (2), the incorrectly
specified variance covariance structure in the analysis was homogeneous first order
Reporting and analysis of repeated measurements in preclinical animals experiments
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autoregressive (homogeneous_AR) as in Eq (4).
homogeneous compound symmetry ¼ s2
1 r r r r
1 r r r
1 r r
1 r
1
2
6
6
6
6
6
6
6
6
6
6
4
3
7
7
7
7
7
7
7
7
7
7
5
ð3Þ
homogeneous first order autoregressive ¼ s2
1 r r2 r3 r4
1 r r2 r3
1 r r2
1 r
1
2
6
6
6
6
6
6
6
6
6
6
4
3
7
7
7
7
7
7
7
7
7
7
5
ð4Þ
Where σ2 in the diagonal represents the constant variance at each five time point of both
structures. For off diagonal value: in the homogeneous_CS structure as in Eq (3), ρ (0� ρ
� 1) is the constant correlation between pairwise time points, and σ2 ρ represents the con-
stant covariance; in the homogeneous_AR as in Eq (4), ρ(j−i) are the correlations between
timej and timei, and σ2ρ(j−i) denotes covariance between timei and timej (e.g., σ2ρ(4−1) is
the covariance between time1 and time4 of the same subject).
iii. separate ANOVA at each time point.
There is no variance covariance structure specified across all time points in this method.
There is no overall analysis for data across all time points, instead, individual ANOVA at
each time point is implemented using data only at that time point respectively.
For analyses (i) and (ii), the PROC MIXED procedure in SAS software (version 9.4; SAS
Institute Inc., Cary, NC) was used. Contrast statements were used to obtain the treatment effect
at each time point from the RMA. The PROC GLM procedure was used to perform separate
ANOVA analysis at individual time points in (iii). The distributions of p-values at each time
point for the three analyses approaches were then plotted and compared based on results from
1000 simulations. The impact of the changing conditions on the type I and type II error rate
was calculated by comparing the proportion of p-values falling below 0.05. Under the null
model, an analysis procedure that controls type I error correctly is expected to generate a p-
value distribution that is uniformly distributed from 0 to 1. It is expected that 5% of observa-
tions will fall between 0.05 and 0, if alpha (type I error rate) is set as 0.05. All simulation and
analysis code are publicly available in Github https://github.com/jingzhao19/Plos-one-i2019.git.
Results
Aim 1: Assessment of the rationale, approaches to analysis, reporting
results and association with meta-factors
Fifth-eight of 200 articles met the criteria of repeated measures design element [4], i.e., used
language that suggested repeated measurement of the outcome on study subjects. As summa-
rized in Table 2, only three of the 58 studies included a rationale of a repeated measurement of
Reporting and analysis of repeated measurements in preclinical animals experiments
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the outcome. All three studies reported explicit interest in the treatment over time in the objec-
tives. Of the 58 studies, 23 studies reported using a repeated-measures analysis (RMA) and 35
studies did not (NoRMA). Twenty of the 23 studies used the term “repeated-measures” to
define RMA studies. Analysis of Variance (ANOVA) at a single time point was the most com-
mon statistical approach employed in the NoRMA studies (31/35).
For both RMA and noRMA, as shown in Table 2, a minority of studies reported assessing
the normality or homogeneity variance, three (3/23: 13%) and two (2/23: 9%) respectively in
RMA, six (6/35: 17%) and ten (10/35: 29%) respectively in noRMA. Precision of estimation
was frequently reported in both RMA (21/23) and noRMA (31/35). RMA studies were more
likely to present data using figures (15/23), while noRMA randomly present data as figures
(12/35) or as tables (14/35). A clear difference was observed in the reporting of the overall
repeated measures model between the RMA and NoRMA studies. RMA studies usually
reported an overall model effect (main effects of treatment, time, or interaction between treat-
ment and time) and could subsequently also report the effect of treatment at single time points.
However, studies that did not do RMA, only reported analysis conducted at individual time
points. This difference is reflected in the data summarized in Table 2. RMA studies presented
overall results mainly by treatment effect (20/23) or treatment-by-time interaction (17/23) and
followed with testing for treatment at individual time points (13/23). All 13 studies that
reported the treatment effect of RMA model also reported the assessment of the treatment
effect at each time point. In the noRMA category, 69% (24/35) articles directly reported testing
for a treatments effect either at specific time points or all measured time points, for at least one
outcome. Additionally, fourteen of 35 studies converted the data to a single overall metric such
as body weight gain (body weight at the endpoint- initial body weight) e.g., [8–11].
Meta factor analyses were applied only in the Bw-dataset in which body weight was the
common outcome S3 Table. The Bw-dataset was also examined either using a repeated
Table 2. The reporting characteristics of 58 biomedical animal experiments with repeated measurement of an outcome.
Category Examined factors RMA studies
(n = 23)
NoRMA studies
(n = 35)
Body weight as one of outcomes in repeated-measures 9 22
Rationale Provided a rationale for including a repeated measures design 3 0
Assumptions Conducted a test for normality 3 6
Conducted a test for equality of variance 2 10
Repeated measures model
results��
Treatment effect 20 NA
Time effect 15 NA
Treatment-by-time interaction effect 17 NA
Single time point result�� Tested at each time point using raw data 13 24
Tested at all time points 13 14
Tested at specific time points only 0 12
No tests conducted at single time point 11 18
Tested using the derived data body weight gain (= weight at end time point weight at
initial time point)
0 14
Data presentation�� Figure only 15 12
Table only 2 14
Figure & table 4 6
Precision estimate included 21 31
RMA: repeated measure analysis. NoRMA: nonrepeated measures analysis. NA: Not applicable.
��As multiple outcomes can occur within a single study, these categories are not mutually exclusive.
https://doi.org/10.1371/journal.pone.0220879.t002
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measure analysis (RMA-BW) or not (NoRMA-BW), and differences between RMA-BW and
NoRMA-BW were detected in the year of publication, journal impact factor in the published
year, and the first 24 months’ citations S4 Table and S2 Fig. In summary, articles that used
RMA tended to be published more recently, in journals with higher impact factor in the pub-
lished year, and to have more citations in the first 24 months’ post publication.
Aim 2: The impact of analysis approach on type I and type II error of
treatment effects estimated at single time points
Here, we only present two representative scenarios for null and alternative simulation analysis.
The results of the remaining 46 scenarios as extended information are available in GitHub
https://github.com/jingzhao19/Plos-one-i2019.git. Each simulation setting was analyzed by
three approaches (i,ii,iii) as described in materials and methods. The distributions of p-values
for testing
1. the overall treatment effect (only applicable for analysis approaches i and ii),
2. treatment-by-time interaction (only applicable for analysis approaches i and ii), and
3. treatment effect at each time point
were identified.
The impact of incorrectly specifying the variance structure when there is no association
between treatment and the outcome with simulation under compound symmetry covariance
structure, ρ = 0.3 and n = 12 is shown in Fig 1. The expected uniform distribution of the p-
value is observable in the first row of Fig 1. The row one data presented in Fig 1 represents an
analysis that correctly models the variance structure of the repeated measurement data i.e., het-
erogeneous compound symmetry variance covariance structure as in Eq (1). Similarly, the
Fig 1. Data analysis using heterogeneous_CS as in Eq (1), homogeneous_CS in Eq (3), and separate ANOVA based on the null model simulation
with ρ = 0.3, n = 12 and a heterogeneous_CS variance covariance structure. Trt: overall treatment effect. Trt�Time: Treatment by Time interaction.
Week 1, Week 7, Week 14, Week 21, and Week 28: p-value distribution at each time point. Proportion = count per bin/1000.
https://doi.org/10.1371/journal.pone.0220879.g001
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uniform distribution of the p-value is observable when the repeated measurements analysis is
ignored and separate ANOVAs for the treatment effects are conducted at each time point as
shown in row three of Fig 1. By comparison, when the true heterogeneous variance structure is
ignored, and instead the modeling approach assumes that the variation in the body weight is
constant over time i.e., the homogeneous variance assumption, the p-value distribution is far
from the expected uniform distribution, especially at the most distal time points, week 1 and
week 28. In particular, the p-value distribution at “week 28” is stochastically smaller (peaked at
smaller p-values and skewed to the right) than the expected uniform distribution. The propor-
tion of p-values < 0.05 is 22.5% with homogeneous_CS as in Eq (3) based on the simulation
results which indicates a much larger than expected type I error rate. This result is associated
with the inappropriate calculation of SEM (the standard error for comparing treatment
means) and estimated SEM based on the homogeneous_CS model. As present in Fig 2, the
SEM across time in heterogeneous_CS and separate ANOVAs exhibited the same SEM trend,
hence similar test results are identified. Alternatively, the estimation of SEMs from homoge-
neous_CS as in Eq (3) was constant across five time points, which is not consistent with the
fact that the variances change over time. Due to the averaging effect across all time points, the
strongest influence of the inappropriate SEM happened at distal time points such as week 1
with left skewed, week 28 which was right skewed.
The results for the alternative model, i.e., a treatment effect does exist, the impact of misspe-
cification of the variance structure for the compound symmetry covariance structure, n = 12
per group and ρ = 0.3 are presented in Fig 3. Focusing first on the correctly specified analysis
in the first row of Fig 3, we can see that the p-values distribution is skewed to the left as
expected. In the 2nd row of Fig 3, the impact of misspecification of the variance structure var-
ies by time point. In the early weeks 1 and 7, the flat and right skewed p-value distributions
indicate lower power (increased type II error). For the important endpoints, the incorrectly
specified homogeneous variance structure is more powerful than the other two analyses meth-
ods at later time points (e.g., week 28). For example, at week 28, the proportion of p-
values< 0.05 is 39.8% with heterogeneous variance based analysis, compared to 63.7% with
the homogeneous based analysis. This should not be construed as a rationale for making the
incorrect assumption as the simulation of the null model indicated homogeneous does not
control type I error correctly making the approach invalid. As shown in Fig 4, the SEM across
time increased in heterogeneous_CS as in Eq (1). The separate ANOVA model had similar
SEM estimation with the heterogeneous_CS structure, which was used to simulate the dataset.
However, the SEM estimation based on homogeneous_CS as in Eq (3) has a completely differ-
ent trend (constant SEM), thus the endpoint become extraordinarily significant and less signif-
icant at week 1 and week 7.
Similar results, differing only in magnitude were observed for all scenarios evaluated and
these are reported in the GitHub https://github.com/jingzhao19/Plos-one-i2019.git for the sce-
narios with different correlations, sample sizes, and covariance structure. The comparison of
the separate ANOVA and the heterogeneous variance repeated measures approach, suggests
that separate ANOVA is less powerful than testing the time effect within the repeated measure-
ments analysis especially at the endpoint week 28. As the correlation between time points ρ
increases, the p-value distribution becomes stochastically larger (less powerful). As sample size
increased, the p-value distribution becomes stochastically smaller (more powerful).
Discussion
Repeated measures on the outcome is a commonly used design element in preclinical animal
experiments [4]. The rationale for incorporating a repeated measurement design element into
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an experiment is generally considered to be of interest in a treatment-by-time interaction or
effective control of subject-to-subject variation [5]. We found that a surprisingly large number
of studies that collected repeated measurement data did not incorporate repeated measure-
ments statistical analysis (35 of 58). It would be interesting to understand the rationale for col-
lecting measurements of the outcome over time; however few authors provided a clear
Fig 2. SEM estimation using heterogeneous_CS as in Eq (1), homogeneous_CS in Eq (3), and separate ANOVA based on the null model
simulation with ρ = 0.3, n = 12 and a heterogeneous_CS variance covariance structure. Week 1, Week 7, Week 14, Week 21, and Week 28: SEM
distribution for pairwise comparisons between treatments at each time point. Proportion = count per bin/1000.
https://doi.org/10.1371/journal.pone.0220879.g002
Fig 3. Data analysis using heterogeneous_CS as in Eq (1), homogeneous_CS in Eq (3), and separate ANOVA based on the alternative model
simulation with ρ = 0.3, n = 12 and a heterogeneous_CS variance covariance structure. Trt: overall treatment effect; Trt�Time: the overall treatment-
by-time interaction; week 1, Week 7, Week 14, Week 21, and Week 28: p-value distribution at each time point. Proportion = count per bin/1000.
https://doi.org/10.1371/journal.pone.0220879.g003
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rationale for the design element. Some investigators were clearly interested in the effect at mul-
tiple time points while others were only interested in the endpoint as evidenced by use of the
weight change outcome. Both the PREPARE guidelines and the ARRIVE guidelines recom-
mended a complete statement of objectives be included in preclinical animal experiments [12,
13], and this would imply inclusion of the rationale for a repeated measures design.
An interesting finding was the number of noRMA studies that used weight change as the
outcome yet reported measuring the outcome at multiple time points, examples include [9, 11,
14]. It is unclear if collection of the unused measurements required additional handling or pro-
cedures that could have adversely impacted the welfare of the experimental animals. Some
repeated outcomes, like food intake do not require additional handling, and therefore addi-
tional data collection is not associated with animal welfare, while others such as body weight
might. The goal of minimization of stress and unnecessary handling of experimental animals
would imply that if the pre-planned analyses did not require multiple measurements then
investigators should avoid measurement for measurement’s sake, if measurement places stress
on the animals [15–17].
We would propose that the rationale for repeated measurements design should be included
in the statement of objectives as it provides a basis for the sample size and additional justifica-
tion animal handling procedures. If repeated measurement of the outcome is not needed to
answer the study hypothesis, then it might be best to not collect the data for animal welfare rea-
sons. When the data are collected, a repeated measurements analysis should be utilized as it
provides the greatest power to detect treatment effects and provides comprehensive informa-
tion from the study design.
After the rationale is clarified, a comprehensive description of the study design serves as a
road map for interpreting the study. This study design description should include a descrip-
tion of the type of design used, a description of how the study was conducted, and each factor
involved in the experiment because the justification for the analysis lies not in the data col-
lected, but in the manner in which the data were collected [18]. Another important component
is how the repeated measure analysis was implemented (e.g., platform, variance structure).
Fig 4. SEM estimation using repeated measures analysis with either heterogeneous_CS as in Eq (1), homogeneous_CS in Eq (3), and separate
ANOVA analysis approaches at each time point based on the alternative model simulation with ρ = 0.3, n = 12 and a heterogeneous_CS variance
covariance structure. Week 1, Week 7, Week 14, Week 21, and Week 28: SEM distribution for pairwise comparison between treatments at each time
point. Proportion = count per bin/1000.
https://doi.org/10.1371/journal.pone.0220879.g004
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However, this information is usually missing. This missing information not only triggers con-
cerns about whether the analysis had been appropriately conducted, but also creates a gap
between investigator and reader. We strongly suggest the authors should provide more infor-
mation to show how the analysis was implemented (e.g., platform, procedure, variance struc-
ture) and provide the rationale that the analysis was appropriately done (e.g., provide residual
plot to show that the heterogeneous variance structure assumption is met before fitting this
heterogeneous variance structure in the model). The authors should also make the code used
for analysis available in order to enhance the reproducibility of the results.
One critical assumption is homogeneity of variance over time. Assessment of homogeneity
of variance is only relevant to RM analysis and is often set as the default algorithm for software
statistical packages. The results of our simulation study demonstrate the need to assess this
assumption and the need to adjust the analysis approach if not valid. Evaluation of the assump-
tion is relatively straightforward by evaluating the observed deviation of observations at each
time point. If the spread increases over time, then the homogeneity assumption is likely vio-
lated. Fortunately, many authors do plot or tabulate these data already, so the information is
readily available. As shown in Figs 1–4 under the condition of heterogeneous variance, a RMA
with homogeneous variance structure is not appropriate to control type I error or type II error
rates. This finding was consistent regardless of covariance size or structure and group size.
Our simulations were based on body weight data extracted from Cho et al. [6], which has vari-
ation that was increasing over time and these data are representative of the data observed in
many preclinical animal experiments. The direction of error varies based on the time point
and the true treatment effect. Based on the data extracted from Cho et al. [6], if analyzed with
the inappropriate homogeneous variance structure, the estimated variance is inflated at earlier
time points, leading to wide confidence intervals in treatment effect sizes and thus less power-
ful tests. On the contrary, the estimated variance with an incorrect homogeneous variance
structure caused shrinkage of the variance and, leading to narrow confidence intervals, larger
test statistics and increased type I error rates. The Cho et al. [6] data showed increasing vari-
ance over time, and this may not always the case; however, increasing variance over time is
very common in practice, such as in body weight measurements. When variance is not strictly
increasing over time, similar results will still hold as long as the variance is not constant over
time. We have only focused on the pattern observed for one outcome, body weight in growing
animals, and although this is a common outcome, the pattern in variance and errors rates we
observed are not reported as generalizable to all. Instead the simulations results illustrate that
investigators should examine the patterns observed in their outcomes and determine what var-
iance structure is appropriate for that outcome and time frame.
Another critical assumption for the single time points and the RM approaches is that of
normally distributed errors assumptions [19]. As discussed by Oberfeld and Frank [20], for
non-normal data, repeated-measure analysis shows clear deviations from the nominal type I
error rate in many conditions, even for sample sizes greater than 50.
Even though the same data with repeated measure design can be analyzed differently (RM
ANOVA or Separate ANOVA), the investigator should be aware that the analysis for group
differences at a specific time point or the analysis of repeated measures over time answers dif-
ferent research questions. For example, over a longer period one group might have a more
favorable outcome than a second group. But at a specific time point after start of therapy the
outcomes might be similar between groups. If the research question specifically aims to com-
pare the treatment effect at a specific time point (e.g., the group difference at 10 weeks only is
specially of interest), single-time point ANOVA at this time point is a legitimate approach to
analysis. However, if the true hypothesis of interest is the treatment effect at multiple time
points, then single-time point ANOVA at each time point is not recommended. Our
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simulation result consistently show that separate ANOVA method yields lower statistical
power for detecting the treatment effect at each of the multiple time points if compared to a
repeated measure analysis method for specific time point analysis. Colloquially, we can think
of the repeated measures analysis as borrowing information from the other time points. Alter-
natively, if the hypothesis focuses on comparing groups over time across the whole process,
repeated measure analysis is more desirable approach. Obviously, this does require a prespeci-
fied hypothesis and research protocol that specifies the outcome of interest. Consequently, we
recommend that repeated measure analysis should be implemented regardless of the goal
which is to understand treatment effect over time or treatment effect at a specific time point if
qualified data is available.
For some designs and research questions it is reasonable that investigators would not
include all time points in their analysis due to the concern of the data quality. For example, the
researchers might not use all time points in the study for a variety of reasons, including sample
size attrition due to mortality or limitations with data quality at certain time points [21]. Addi-
tionally, researcher might excluded certain time points for statistical reasons for example if the
data distribution of the time point of interest was different than other time points (e.g., time
points 1-5 were normal distributed but the time point 6 is of interest and it has a bimodal
distribution).
Other issues related to repeated measure analysis such as multiple testing, missing value
also should be aware by researcher. Even though multiple testing correction [22] is not the
focus in this paper, the impact of multiplicity in the discovery framework of many preclinical
animal experiments should be considered when interpreting findings [23, 24]. Missing data is
another common problem in preclinical repeated measures designs and the application of
multilevel models over repeated measures ANOVAs for datasets with missing values are spe-
cifically discussed in [25]. A sphericity corrections (e.g. Greenhouse-Geisser) should be specifi-
cally considered when repeated measure ANOVA is implemented either PROC GLM in SAS
and ezANOVA in R [25–27].
The different approaches to analysis (no RMA or RMA) inherently lead to different report-
ing styles. For the RMA studies, the overall treatment, time, and treatment-by-time interaction
should be expected to be reported first, and then treatment effect at individual time points
should follow. For the main effects and the treatment effect at each time point, the effect size
and precision should be provided in addition to any hypothesis testing. This approach to
reporting provides a comprehensive summary of the findings and maximizes the information
obtained from the animals in the discovery phase of research. Unfortunately, not all reviewed
RMA studies have both components (overall and individual test results). Partial information
may be missing, such as having no individual test results e.g., [28–30]. It is not surprising that
reporting was incomplete as poor reporting is common in preclinical animal studies hence the
need for reporting guidelines like ARRIVE [12, 13].
In contrast to RMA, the studies in NoRMA directly reported the significance at specific
time points. This style of reporting is expected because researchers analyzed the data separately
using a subset of the data at each time point. However, regrettably the reporting of partial
results was common and the majority of these reported results were significant, suggesting
selective reporting of significant results. This reporting strategy without clarification created
two alternative questions: was the lack of reporting due to testing at selected time points or
was it due to non-significance? Again, such selective reporting reduces the amount of informa-
tion available for translational use of the study results and does not maximize the value of
resources, including animals used in the study [31, 32].
The impact of poor reporting and analysis of other design elements such as approaches to
allocation (random or not) and outcome assessment (blinded or not) on the reproducibility of
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research has been discussed in numerous studies [31, 33–35]; however, we are unaware of
prior studies that have evaluated the reporting of repeated measures designs and the impact of
including but ignoring the repeated measurement design element in preclinical research. As
repeated measures create non-independent observations which has implications for error esti-
mation, which can, in turn, impact inferential statistics based on error estimates (e.g., p-values)
it is important to understand how and why investigators are using a repeated measures design
element and any role this might play in the reproducibility of results from preclinical animal
research. Meta-factor analysis was used to explore whether there is association between meta-
factors and consistency of experimental design. The association was clearly identified: articles
that used RMA tended to be published more recently, in journals with higher impact factor in
the published year, and to have more citations in the first 24 months’ post publication. This
association illustrates that consistent experimental design is also important factor associate
with journal impact factor and paper citation, thus both researcher and journal reviewer
should be aware to improve the impact of the paper and journal.
Conclusion
Key elements of a repeated measures design, such as rationale, methodology, and results were
frequently reported incompletely in the 58 studies with repeated-measure design, and this
raises concepts of the validity of results from studies that reported repeated-measures. The
findings of this study were summarized as follows:
1. Although repeated measurement of the outcome is common in preclinical experiments the
rationale for inclusion is rarely reported.
2. Similarly, checking the assumption of the analysis; and covariance structure used to do the
repeated-measures analysis was not described in any of the studies. Raising concerns about
the reproducibility of the results.
3. Conduct of a RMA consistent with the study design and patterns of variance can control
the error rates in preclinical experiments. In particular the assumption of homogeneous
variance structure that is the default for many statistical packages should be assessed prior
to conducting the repeated-measure analysis by checking the plots of data with a measures
of variation. If this assumption is found not to be met, appropriate adjustments to the statis-
tical models must be considered. This might be applying sphericity corrections (e.g. Green-
house-Geisser) for repeated measures ANOVAs or incorporation of nonhomogenous
covariance structures (e.g. AR1) within the model specification of multilevel models.
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